Last reviewed · How we verify
Vaxine Pty Ltd — Portfolio Competitive Intelligence Brief
2 marketed
0 filed
2 Phase 3
0 Phase 2
5 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| HBsAg | HBsAg | marketed | Vaccine | Hepatitis B surface antigen (HBsAg) | Immunology / Infectious Disease | |
| Recombinant influenza hemagglutinin | Recombinant influenza hemagglutinin | marketed | Recombinant protein vaccine | Influenza hemagglutinin | Immunology / Infectious Disease | |
| Commercial Hepatitis B vaccine | Commercial Hepatitis B vaccine | phase 3 | Vaccine | Hepatitis B surface antigen (HBsAg) | Immunology | |
| SpikoGen vaccine | SpikoGen vaccine | phase 3 | Recombinant protein vaccine | SARS-CoV-2 spike protein | Immunology / Infectious Disease |
Therapeutic area mix
- Immunology / Infectious Disease · 3
- Immunology · 1
- Other · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Pfizer · 2 shared drug classes
- GlaxoSmithKline · 2 shared drug classes
- Henogen · 2 shared drug classes
- Henry M. Jackson Foundation for the Advancement of Military Medicine · 2 shared drug classes
- Tan Tock Seng Hospital · 2 shared drug classes
- The University of Hong Kong · 2 shared drug classes
- BiondVax Pharmaceuticals ltd. · 1 shared drug class
- BioNTech · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Vaxine Pty Ltd:
- Vaxine Pty Ltd pipeline updates — RSS
- Vaxine Pty Ltd pipeline updates — Atom
- Vaxine Pty Ltd pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Vaxine Pty Ltd — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/vaxine-pty-ltd. Accessed 2026-06-10.